Has Vandana Madkan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $327,102 in general payments to Vandana Madkan, MD across 781 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vandana Madkan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vandana Madkan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vandana Madkan, MD

Dermatology · Sugar Land, TXNPI 1659691772

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $250,541 of the $327,102 with a category attached, or 76.6%. 25 manufacturers reported payments, led by Amgen at 49.3% of the total. Reporting peaked in 2023 at $105,789 and has fallen 65.4% since, to $36,592 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$327,102in general payments, 2019–2025

Across 781 payments — averaging $418.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$161K
Pfizer$77K
Bristol Myers Squibb$43K
AbbVie$19K
Novartis$5K
Dermavant Sciences, Inc.$4K
plus $17K from 19 others

$1,562,126in research payments, 2019–2025

Across 240 payments — averaging $6508.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$705K
Pfizer$666K
AbbVie$115K
Bausch Health US, LLC$57K
Incyte Corporation$16K
Amgen$2K
plus $1K from 1 others

What the payments were for

Consulting fees$27,4998%
Speaking & faculty fees$250,54177%
Travel & lodging$30,3799%
Food & beverage$18,5046%
Education$1790%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	155	$161,392
Pfizer	66	$77,192
Bristol Myers Squibb	42	$42,579
AbbVie(2 entities)	135	$19,165
Novartis	50	$5,463
Dermavant Sciences, Inc.	28	$4,286
Incyte Corporation	31	$4,140
Arcutis Biotherapeutics, Inc.	24	$3,192
Sun Pharmaceutical Industries Inc.	24	$3,079
Organon	16	$1,299
Johnson & Johnson	41	$1,109
E.r. Squibb & Sons, L.L.C.	38	$748
Regeneron Healthcare Solutions, Inc.	24	$613
Galderma Laboratories, L.p.	18	$538
UCB, Inc.	15	$533
Lilly USA, LLC	24	$482
LEO Pharma Inc.	14	$387
Sanofi	14	$348
VYNE Pharmaceuticals Inc.	2	$163
Ortho Dermatologics, A Division Of Bausch Health US, LLC	9	$155
Springworks Therapeutics, Inc.	3	$77
Boehringer Ingelheim	3	$75
Medline Industries LP	1	$29
Biofrontera Inc.	2	$28
Kyowa Kirin, Inc.	2	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Otezla$183,124
LITFULO$39,406
CIBINQO$35,870
Skyrizi$12,256
VTAMA$4,833
COSENTYX$4,353
Humira$3,713
ZORYVE$2,767
Rinvoq$545
OPZELURA$248
AMZEEQ$150
NEMLUVIO$143
Bimzelx$134
Sotyktu$110
ILUMYA$108
ABSORICA LD$108
BLU-U$108

How this compares

$327,102 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024

$87,047

Medicare patients

353

Services billed

1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	27	$102,488
Fluocinonide	191	$7,545
Tacrolimus	21	$3,175
Clobetasol Propionate	49	$1,945
CiclopiroxCiclopirox Olamine	72	$1,625
Clindamycin Phosphate	49	$1,604
Ketoconazole	97	$1,352
Triamcinolone Acetonide	108	$1,185
Desonide	11	$771
Tretinoin	11	$689
Doxycycline Monohydrate	37	$625
Metronidazole	13	$583
Hydrocortisone	70	$449
Mupirocin	46	$359
Minoxidil	23	$229

Paid to pharmacies, not to this prescriber.

Other dermatology in Sugar Land

Michael SonabendSugar Land$184K
Jennifer MaenderSugar Land$127K
Edward LainAustin$2.5M
William CragunSan Antonio$2.2M
Alpesh DesaiHouston$1.6M
Craig TellerBellaire$1.3M
Jennifer CatherDallas$1.3M
Emily BeckerSan Antonio$1.2M
Ross RaduskyDallas$1.2M
Joseph MerolaDallas$1.2M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →